Multidrug-Resistant Candida auris Infections in Critically Ill Coronavirus Disease Patients, India, April–July 2020

  29 August 2020

In New Delhi, India, candidemia affected 15 critically ill coronavirus disease patients admitted to an intensive care unit during April–July 2020. Candida auris accounted for two thirds of cases; case-fatality rate was high (60%). Hospital-acquired C. auris infections in coronavirus disease patients may lead to adverse outcomes and additional strain on healthcare resources.

The ongoing coronavirus disease (COVID-19) pandemic has overwhelmed healthcare systems worldwide. Reports from China and New York have highlighted the concern for nosocomial infections, primarily bacterial, in critically ill COVID-19 patients. Secondary Candida spp. bloodstream infections in COVID-19 patients with prolonged intensive care unit (ICU) stays have not been documented. However, a new concern coinciding with the brisk expansion of critical care facilities for COVID-19 patients is the potential for nosocomial spread of Candida auris infections. C. auris is a global health threat because of its ability to colonize skin, persist in environments, cause nosocomial outbreaks, and lead to severe disease with high mortality rates.

Further reading: CDC
Author(s): Anuradha Chowdhary, Bansidhar Tarai, Ashutosh Singh, and Amit Sharma
Healthy Patients  


Unrestricted financial support by:


Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre


Global Ambassador Network

Welcome at the AMR Insights Ambassador Network!

The AMR Insights Ambassador Network is a growing, distinctive group of professionals who stand out for their commitment, willingness to cooperate and open attitude to combat Antimicrobial resistance (AMR).

More information and free-of-charge registration
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!